In recognition of their past contributions to the field of international infectious diseases and in anticipation of their future impact on the discipline, these individuals are recognized as ISID Emerging Leaders in International Infectious Diseases.
Joseph Agboeze, Nigeria
Dr Joseph Agboeze is an Obstetrician /Gynaecologist and a Field epidemiologist from Nigeria. His current main scope of work is on Prevention of mother to child transmission of HIV (PMTCT) and Lassa fever. He is interested in infection prevention and control, including modelling of infectious diseases.
Tinsae Alemayehu, Ethiopia
Dr Tinsae Alemayehu is a pediatric infectious diseases specialist and adjunct associate professor working in Addis Ababa, Ethiopia. His area of research interest is antimicrobial stewardship with relevance to childhood infections. He is also the current vice president of the African society of pediatric infectious diseases (AfSPID)."
Amal Al-Maani, Oman
Dr. Amal Al Maani is a Senior Consultant in Pediatric Infectious Diseases and is the Director of the central Department of Infection Prevention & Controlat the Ministryof Health, Sultanate of Oman.She is the winner of the SASAKAWA global health price for 2021 for her work in the field of infection control and antimicrobial resistance)
Afreenish Amir, Pakistan
Afreenish Amir, a medical microbiologist with over ten years of experience in clinical microbiology and infectious diseases, is currently working as Lab Coordinator in CDC GHSA project at NIH Pakistan. She graduated in 2005 with a Masters of Philosophy (Microbiology), and is currently pursuing a PhD in Microbiology. She is a GIBACHT fellow, a Harvard alumna and a Master trainer for Biosafety (PBSA) and Infection prevention/control.
Fatima Aziz, Pakistan
Fatima Aziz is an Assistant Manager (Research) at the Department of Paediatrics and Child Health, Infectious Disease Research Laboratory, Aga Khan University. Her research focuses on infectious diseases and malnutrition. Currently she is serving as an American Society for Microbiology (ASM) Young Ambassador to Pakistan. She is also working with Global Health Security Agenda Consortium as a Membership Coordinator. She is International Federation of Biosafety Associations (IFBA) certified professional and a global mentor for Biorisk management. She has been awarded a PandemicTech fellowship to develop technology-driven communications tools that improve biosafety and biosecurity capacity in Pakistan.
Muge Cevik, United Kingdom
Bio Coming Soon
Esmita Charani, United Kingdom
Esmita is the Senior Lead Research Pharmacist within the faculty of Medicine at Imperial College London at the NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance. She a visiting Researcher at Haukeland University Hospital, Bergen Norway, and adjunct faculty at Amrita Institute of Medical Sciences, Kerala India, where she is involved in helping implement and investigate national antibiotic stewardship programmes. She is a Global Health Fellow with the Office of the Chief Pharmaceutical Officer for England and advises on the global health partnerships between the NHS and healthcare facilities in Uganda, Ghana and Tanzania. She is also an ESCMID (European Society for Clinical Microbiology and Infectious Disease) Fellow.
She is co-investigator on the ESRC award (2017-2021): Optimising antibiotic use along surgical pathways: addressing antimicrobial resistance and improving clinical outcomes (in England, Scotland, Rwanda, India & South Africa). Esmita gained her Masters (MPharm Hons) from Pharmacy at University College London, her MSc in Infectious Diseases from the London School of Hygiene and Tropical Medicine and her PhD from Imperial College London.Her doctoral thesis investigated antimicrobial stewardship across India, Norway, France, Burkina Faso and England.
Bethany Davies, United Kingdom
Bio Coming Soon
Angel Desai, United States
Dr. Angel Desai is a physician who recently completed her infectious diseases clinical research fellowship at Massachusetts General Hospital/Brigham & Women's Hospital in Boston, MA. Apart from her clinical responsibilities, she has been conducting research with ProMED and HealthMAP as well as the International Society for Infectious Diseases since 2017 where she focuses on leveraging informal surveillance methodologies to discern epidemiological trends on emerging diseases and outbreaks, particularly among displaced and other vulnerable populations. Her other work includes global infection prevention and control measures in resource-limited settings with an interest in high consequence pathogens.
Angel obtained her Bachelor of Science in Foreign Service from Georgetown University in 2007 and M.D. from the University of Illinois at Chicago in 2013 where she helped to found a global health pathway for medical students. She completed her internal medicine residency at the University of Washington where she was involved with research on the impacts of climate change on global disease distribution. She is currently pursuing a Master of Public Health from the Harvard T.H. Chan School of Public Health and is an Emerging Leader in Biosecurity Initiative Fellow through the Johns Hopkins Center for Health Security.
Abiodun Egwuenu, Nigeria
Abiodun Egwuenu is an epidemiologist working with the Nigeria Centre for Disease Control, which is mandated to coordinate the Antimicrobial Resistance response in Nigeria. At the inception of Nigeria’s AMR response journey, she co-coordinated the Antimicrobial Resistance situation analysis and National Action Plan. She has organized the national Antimicrobial Resistance Technical Working Group meetings to drive strategies to improve the national response to Antimicrobial Resistance. This group reviews data to drive public health policy aimed at limiting drug-resistant infection in the country, West Africa and in collaboration with other countries.
She works with a national network of hospitals designated as AMR sentinel surveillance sites: collecting data on AMR and AMU and submitting the same to the GLASS-WHO. She is the AMR Surveillance Fleming Fund alumnus for human health and technical lead for several grants.
Elita Jauneikaite, United Kingdom
Dr Elita Jauneikaite is a Senior Research Fellow in Bacterial Genomics and Epidemiology at Imperial College London, UK. Her research focuses on evolution of bacterial pathogens, antimicrobial resistance and how bacterial genomics can be translated into clinical and public health settings. Elita is investigating the disease-causing Group B Streptococcus (GBS), where she is using whole genome sequencing, bioinformatic analyses and molecular biology techniques to inform on evolution, mother-to-baby transmission and antimicrobial resistance patterns of this pathogen. Elita also leads genomics work investigating outbreaks and pathogenicity of other bacterial pathogens including E. coli, K. pneumoniae, methicillin-susceptible S. aureus,S. argenteus,S. pyogenesandS. pneumoniae. Elita is also a Research Lead for Priority Pathogens theme in the National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London, UK.
Jasmin Islam, United Kingdom
Dr Jasmin Islam qualified from The Royal Free and University College Hospital, London before training in Infectious Diseases and Medical Microbiology. In her current role asNIHR Clinical Lecturer, she is interested addressing the global burden of antimicrobial resistance, by understanding how data can inform antibiotic stewardship policies at the local, national and international level. She has worked with teams in Zambia, Egypt and the UK.
David Moore, South Africa
Dr. David Moore is a Paediatric Infectious Diseases specialist currently working in Soweto, South Africa, at Chris Hani Baragwanath Academic Hospital. He has over 20 years of experience working in the public health sector, and has special interests in vaccine-preventable diseases, pneumonia, tuberculosis and HIV.
Vrinda Nampoothiri, India
Dr Vrinda Nampoothiri is a Doctor of Pharmacy graduate (2016) and has been working very closely with the Antimicrobial Stewardship (AMS) program right from its inception at Amrita Institute of Medical Sciences, Kochi, Kerala, India, playing a key role in the development of the clinical pharmacist driven audit of antimicrobials and various other quality improvement initiatives in the hospital, in addition to providing AMS training to pharmacy students, pharmacists and other health care professionals. She is currently pursuing her PhD under Amrita Vishwa Vidyapeetham University, India exploring the roles played by pharmacists in AMS program in different countries and how their role in the program can be improved in Kerala. Dr Nampoothiri is also working on research projects in collaboration with universities in India, UK and South Africa.
Muhammed Niyas, India
Dr. Niyas is currently working as an Associate Consultant in Infectious Diseases at KIMSHEALTH, Thiruvananthapuram, Kerala, India. He is a physician scientist involved both in clinical infectious diseases and research in infectious diseases. His areas of interests include emerging infections, antimicrobial resistance and antibiotic stewardship. He was instrumental in the identification of the first Zika virus outbreak in the state of Kerala.
Christina Obiero, Kenya
Dr. Christina W. Obiero is a medical doctor (University of Nairobi, Kenya) with public health training from the Johns Hopkins Bloomberg School of Public Health. She currently works as a clinical researcher at the Kenya Medical Research Institute – Wellcome Trust Research Program in Kilifi, Kenya, where she has led/co-led several research projects including investigating the safety, pharmacokinetic and immunogenicity profile of antimicrobials and vaccines. Dr. Obiero is also undertaking her PhD work at the University of Amsterdam, Netherlands, and her research focuses on the diagnosis and management of serious childhood infections in sub-Saharan Africa and aims to improve treatment guidelines and health outcomes. She is a member of the Delta Omega Alpha Chapter (Bloomberg School of Public Health).
Laura Oliveira, India
Dr Laura Oliveira, MSc, PhD, is a Postdoctoral Fellow at the Microbiology Institute of the Federal University of Rio de Janeiro, and since the beginning of her career, she has been involved in the study of the molecular epidemiology, antimicrobial resistance, and virulence potential of gram-positive cocci, especially Streptococci, isolated from humans and animals to improve the surveillance and diagnosis of infectious diseases and to inform control strategies and vaccine design. Dr Laura has been awarded with 10 national and international awards, being the most important, the International Veterinary Vaccinology Network (IVVN) Fellowship for women postdoctoral researchers from low-and-middle income countries (LMICs) and the BactiVac Catalyst Training Award. She is a member of the first cohort of the Future Leaders Against AMR Programme and she is the current ASM Young Ambassador of Science to Brazil.
Tatiana Pinto, Brazil
Prof. Tatiana Pinto has a PhD in Microbiology and is currently an Assistant Professor in Universidade Federal do Rio de Janeiro (UFRJ), Brazil. Her research aims to gather data on virulence and antimicrobial resistance traits among Streptococcus agalactiae and Streptococcus pneumoniae isolates circulating in Brazil, by uncovering novel aspects of the biology of these microorganisms that are important to trace the epidemiological evolution of epidemic and sporadic clones, as well as to help designing improved therapeutic and prophylactic measures against pediatric streptococcal infections. Dr Pinto is also an enthusiastic of public engagement and science communication activities, and is an active member of other international scientific societies, including the American Society for Microbiology.
Laura Talarico, Argentina
Dr. Laura Talarico is an investigator from the National Scientific and Technical Research Council in Argentina. She obtained her Ph.D. in Biological Chemistry for studies on the evaluation and characterization of natural compounds for anti-dengue virus activity. She currently works at the Department of Medicine, Ricardo Gutierrez Children’s Hospital, and her research mainly focuses on the role of B and T lymphocytes in dengue and zika virus infections. The ultimate aim of her work is to identify viral, immunological and physiological factors involved in dengue and zika infections that will likely contribute to better assessment of flavivirus infections in vulnerable populations.
Jason Trubiano, Australia
Dr. Jason Trubiano is an Infectious Diseases Physician and Director of Antimicrobial Stewardship and Drug and Antibiotic Allergy Services at Austin Health. He is a postdoctoral fellow at The National Centre for Infections in Cancer (Peter MacCallum Cancer Centre) and NHMRC Early Career Fellow at the University of Melbourne.His research examines Antimicrobial Stewardship health services interventions in penicillin allergy and role of novel diagnostics in severe antibiotic reactions.
Sophie Yacoub, Vietnam
Prof. Sophie Yacoub is a Consultant Physician in Infectious Diseases and General Medicine and is the Dengue Research Group Head at the Oxford University Clinical Research Unit (OUCRU), based in Ho Chi Minh City, Vietnam. She is as an Adjunct Assistant Professor at the Lee Kong Chian School of Medicine in Singapore and holds an honorary Consultant appointment at London North West University Healthcare NHS Trust in the UK.
She was awarded a PhD in 2016, through the Imperial College Wellcome Trust Clinical PhD Programme and has a Masters degree from the London School of Hygiene and Tropical Medicine. She is a member of the Royal College of Physicians in London. She has clinical academic experience in a variety of tropical diseases, including Chagas disease, malaria and dengue, having worked in northern Australia, Kenya, Tanzania and Honduras.Her work has been supported by grants from the Wellcome Trust, NMRC Singapore, the WHO, British Heart Foundation and the Royal Society of Tropical Medicine.
Dalal Youssef, Lebanon
Dalal Youssef is a seasoned epidemiologist with over 10 years of experience in the field. She is a biologist who graduated in 2011 with a Master of Public health (Epidemiology and biostatistics) from the Doctoral School for sciences and technologies. She held also an international master's in road safety management from Saint Joseph University in collaboration with the Renault foundation. She is officially an International Federation of Biosafety Associations (IFBA) certified Biorisk Management professional and she is currently finalizing her Ph.D. in Public Health at the University of Bordeaux (ISPED). She began her professional careerin 2012 in the epidemiological surveillance program as a specialist in epidemiology and then she worked at the preventive medicine service during the COVID-19 pandemic.
She is currently the manager of the Lebanese clinical trials program. Her work in diverse departments (surveillance, preventive medicine, and clinical trials) has provided her with combined expertise in surveillance systems, outbreak investigation, emergency preparedness, early warning, clinical research, and rapid response to emerging and re-emerging diseases. In 2017, she has been involved in the process of converting disease surveillance reporting from a cumbersome paper-based system to a web-based electronic platform (DHIS-2) and the implementation of event-based surveillance. She is also a lecturer at the National Pedagogical Institute for Technical Education since 2017. She has been involved in much operational research in the area of emerging and re-emerging infectious diseases, surveillance, vaccine-preventable diseases, injury prevention, occupational health, and mental health. She has several scientific publications in her areas of expertise and has first-authored over 15 research articles published in international, peer-reviewed journals.She is serving as an editorial member and reviewer of several international journals and has directed several dissertations for traffic major students since 2017.
Is ISID peer-reviewed? ›
The International Journal of Infectious Diseases (IJID) One Health (OH), an open access, peer-reviewed journal published monthly online by the International Society for Infectious Diseases (ISID), promotes original research and perspectives related to One Health.What is an emerging infectious disease and what are 2 reasons it might be emerging? ›
Emerging infectious diseases are infections that have recently appeared within a population or those whose incidence or geographic range is rapidly increasing or threatens to increase in the near future. Emerging infections can be caused by: Previously undetected or unknown infectious agents.What are current emerging infectious diseases? ›
Emerging diseases include HIV infections, SARS, Lyme disease, Escherichia coli O157:H7 (E. coli), hantavirus, dengue fever, West Nile virus, and the Zika virus. Reemerging diseases are diseases that reappear after they have been on a significant decline.Who goals for combating emerging and re emerging infectious diseases? ›
The objectives of Preventing Emerging Infectious Diseases: A Strategy for the 21st Century are organized under four goals: surveillance and response, applied research, infrastructure and training, and prevention and control.Can you trust peer-reviewed information? ›
Peer-review is by no means perfect. It is itself subject to bias, as most things in research are. Evidence from a peer-reviewed article does not make it reliable, based only on that fact.How trustworthy are peer-reviewed? ›
While there are a lot of factors to consider, finding out if the article is peer-reviewed can be a quick litmus test for credibility. However, just because a paper is published in a “peer-reviewed journal,” does not mean that the paper is completely fact-checked, unbiased, or correct.What are 3 factors contributing to emerging infectious diseases? ›
The spread of existing infections and the emergence of new ones in many areas of the world can be caused by poor sanitary conditions, hygiene and a lack of clean drinking water.What are 5 emerging diseases? ›
- Nipah and Hendra viruses.
- Additional hantaviruses.
- Tick-borne hemorrhagic fever viruses (Bunyaviruses, Flaviviruses)
- Tick-borne encephalitis complex flaviviruses.
- Tuberculosis, including drug-resistant tuberculosis.
- Influenza virus.
- Other rickettsias.
- Rabies virus.
Five infectious causes ranked among the top ten killers in LMICs: lower respiratory infections (3.4 million deaths), HIV/AIDS (2.6 million deaths), diarrheal diseases (1.8 million deaths), tuberculosis (1.6 million deaths), and malaria (1.1 million deaths) (Table 3).What are 75% of emerging infectious diseases? ›
Infectious diseases remain a significant cause of mortality and morbidity globally; approximately 75% of emerging infectious diseases (EIDs) are zoonoses .
What are three examples of emerging infection? ›
- Coronavirus infections such as COVID-19, SARS, and MERS.
- HIV infections.
- Lyme disease.
- Escherichia coli (E. coli) O157:H7.
- Dengue fever.
- West Nile virus.
- Zika virus.
- Changes in global population demographics and distribution. ...
- Human behavior and societal change. ...
- Environmental change and land use. ...
- Chronic manifestations of infectious diseases. ...
- Enhanced pathogen detection. ...
- Microbial evolution. ...
- Breakdown of the public health system and bioterrorism.
- #1 Handle & Prepare Food Safely. Food can carry germs. ...
- #2 Wash Hands Often. ...
- #3 Clean & Disinfect Commonly Used Surfaces. ...
- #4 Cough and Sneeze into a Tissue or Your Sleeve. ...
- #5 Don't Share Personal Items. ...
- #6 Get Vaccinated. ...
- #7 Avoid Touching Wild Animals. ...
- #8 Stay Home When Sick.
Three steps are involved in responding to a disease outbreak -- surveillance, evaluation, and implementation of control measures. Surveillance begins with accurate diagnosis and requires open lines of communication among doctors, scientists, and government officials.What is the conclusion of emerging diseases? ›
Conclusion. The threat of emerging infectious diseases will continue to cloud our future, with new and recurring infections ever present to wreck havoc on human populations. The pathogens that are the threat of the future may be ones that were previously thought contained or even eradicated.What is the downside of peer review? ›
Con: Peer reviews can create confusion
Being reviewed by peers means that one person will no longer be evaluating someone's performance. While the goal is to create more balanced, accurate feedback, the downside is that multiple reviewers can cause confusion. People may get clashing feedback.
The Don'ts of Peer Review
Don't make any personal reference to the authors and avoid exclamation points or an emotional style. Peer review is not an emotional process. Don't say things like, "I don't believe it" and "I find this unconvincing. I find these results underwhelming or trivial or not important."
A rude peer-review is unfair and biased for reasons unrelated to the quality of the manuscript such as the nationality, gender, English language criticism, opposite theory or conflicts of interest [2, 18]. It is a discouraging, insulting, dishonest and unhelpful review with impossible requests to the authors.Do peer reviewers make mistakes? ›
People make mistakes.
Even if every person involved in the publication of a manuscript catches 99% of all errors, it's still possible that some errors will go unnoticed. This likelihood of course goes up when authors/reviewers are careless, but it can never be eliminated entirely even with very meticulous review.
Peer reviews require honesty and trust. Make sure that peers who wish to evaluate their teammates will be able to do so with anonymity from both managers and their peers.
How do you know if a peer-reviewed article is credible? ›
- An author who is an expert or a well-respected publisher (such as the NY Times or Wall Street Journal).
- Citations for sources used.
- Up-to-date information for your topic.
- Unbiased analysis of the topic (i.e. author examines more than one perspective on the issue).
The world's deadliest infections, including Tuberculosis, Malaria and HIV/AIDS, have been considered as the "Big Three" infectious diseases (BTIDs). With leading infections and deaths every year, the BTIDs have been recognized as the world's greatest pandemics.What are the 4 causes of infectious diseases? ›
- Bacteria. These one-cell organisms are responsible for illnesses such as strep throat, urinary tract infections and tuberculosis.
- Viruses. Even smaller than bacteria, viruses cause a multitude of diseases ranging from the common cold to AIDS.
- Fungi. ...
- HIV infections.
- Lyme disease.
- E. coli.
- Dengue fever.
- West Nile virus.
- Zika virus.
- Chlamydia. 1/15. This sexually transmitted disease affects men and women. ...
- Influenza A and B. 2/15. Sudden fever and chills, muscle aches, headache, tiredness, sore throat, congestion. ...
- Staph. 3/15. ...
- E. Coli. ...
- Herpes Simplex 1. 5/15. ...
- Herpes Simplex 2. 6/15. ...
- Shigellosis. 7/15. ...
- Syphilis. 8/15.
Cardiovascular disease is the top cause of death globally. In the map we see death rates from cardiovascular diseases across the world.What are the 4 earliest known infectious diseases? ›
The Rigveda (about 1500 BC) refers to TB and leprosy, the Egyptian “Ebers papyrus” (about 1500 BC) mentions leprosy, Thucydides of Greece (430 BC) mentions the plague, the Bible (Leviticcus 13.2) talks about leprosy and the Romans describe malaria.What are the 6 killer diseases? ›
Of great importance to public and child health are the vaccines against the so-called six killer diseases of childhood-measles, pertussis, diphtheria, tetanus, tuberculosis and poliomyelitis.What is the fastest growing infectious disease in the US? ›
Lyme disease is the most common and fastest-growing vector-borne disease in the United States.What causes 80% of all infectious diseases? ›
"About 80% of infectious diseases are transmitted by unclean hands touching contaminated surfaces.
What are the emerging infectious diseases of the 21st century? ›
Seven agents that have made a significant appearance, particularly in the 21st century, are reviewed, including: Ebola and Marburg hemorrhagic fevers, human monkeypox, bovine spongiform encephalopathy, severe acute respiratory syndrome (SARS), West Nile virus, and avian influenza.What are the 3rd world infectious diseases? ›
- Neglected diseases.
- Intestinal parasites.
Over the past 30 years, at least 30 new infectious diseases have emerged to threaten the health of millions of people across the globe. The major challenge to combat these infections is that for many of them, there is no specific treatment or cure or vaccine.Is monkeypox an emerging disease? ›
Monkeypox: An Emerging Disease.How can emerging diseases be prevented? ›
Public health measures typically involve eliminating the pathogen from its reservoir or from its route of transmission. Those measures include ensuring a safe water supply, effectively managing sewage treatment and disposal, and initiating food safety, animal control, and vaccination programs.Which of the following would not be considered an emerging disease? ›
Which of the following would NOT be considered an emerging disease? Answer d. Tuberculosis would not be considered an emerging disease.What are 10 examples of infectious diseases? ›
- Campylobacter Infection.
- Hepatitis A.
- Hepatitis B.
- Hepatitis C.
- Novel Coronavirus (COVID-19)
- Influenza (Flu)
- Meningococcal Disease.
- Immunise against infectious diseases.
- Wash and dry your hands regularly and well.
- Stay at home if you are sick.
- Cover coughs and sneezes.
- Clean surfaces regularly.
- Ventilate your home.
- Wash your hands well. ...
- Cover a cough. ...
- Wash and bandage all cuts. ...
- Do not pick at healing wounds or blemishes, or squeeze pimples.
- Don't share dishes, glasses, or eating utensils.
- Avoid direct contact with napkins, tissues, handkerchiefs, or similar items used by others.
Emerging infectious diseases can be defined as infectious diseases that have newly appeared in a population or have existed but are rapidly increasing in incidence or geographic range, or that are caused by one of the NIAID Category A, B, or C priority pathogens.
What is the impact of emerging infectious diseases? ›
Factors associated with the emergence of these infectious agents include changes in the environment, changes in human behavior, and the emergence of antimicrobial resistance . EIDs cause a huge economic crisis and public health problems in the world [3,4].What is the impact factor of emerging infectious diseases CDC? ›
The journal is indexed in PubMed, MEDLINE, Web of Science: Science Citation Index Expanded, and Scopus. The journal has a 2021 impact factor of 16.162.Why should one help prevent the spread of free emerging disease? ›
New pathogens will continue to emerge and spread across regions and will challenge public health as never before signifying grim repercussions and health burden. These may cause countless morbidities and mortalities, disrupting trade and negatively affect the economy.Why is it important to be aware of emerging infectious diseases? ›
A better understanding of risk factors for the development of infection and disease will provide new opportunities for disease prevention. A better understanding of relationships between infectious agents and some chronic diseases will lead to new strategies for preventing and treating chronic diseases.What is emerging infectious disease synopsis? ›
An emerging infectious disease (EID) is defined as a disease caused by a pathogen that has not been observed previously within a population or geographic location.Is clinical infectious diseases peer-reviewed? ›
Clinical Infectious Diseases is a peer-reviewed medical journal published by Oxford University Press covering research on the pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms, and treatment of diseases caused by infectious agents.Is this a peer-reviewed source? ›
Identifying if a Journal is Peer Reviewed
One of the best places to find out if a journal is peer-reviewed is to go to the journal website. Most publishers have a website for a journal that tells you about the journal, how authors can submit an article, and what the process is for getting published.
Emerging Infectious Diseases, an open access, peer reviewed journal published monthly by the Centers for Disease Control and Prevention, promotes the recognition of new and reemerging infectious diseases around the world and improves the understanding of factors involved in disease emergence, prevention, and ...Which information source is peer-reviewed? ›
Scholarly articles are those that are reviewed by multiple experts from their related field(s) and then published in academic journals.Is Mayo Clinic considered peer-reviewed? ›
Continuously published since 1926, Mayo Clinic Proceedings is a peer-reviewed journal, ranked among the top 10% of the 160 clinical journals in the Medicine, General and Internal category.
How do you tell if a medical study is peer-reviewed? ›
Look to left of the title, and if you find a referee shirt icon, that means that the journal is peer-reviewed or refereed. 5. The publisher's website for the journal should indicate whether articles go through a peer review process. Find the instructions for authors page for this information.What is the impact factor of Eid? ›
Abstracting and Indexing
The journal has a 2021 impact factor of 16.162.
Library databases such as CINAHL, Academic Search Complete, or Social Sciences Full Text are the best places to locate peer-reviewed articles. Most databases provide a limiter or check-off box that allows you to limit your results to peer-reviewed journals.Where can I find peer reviews? ›
- Check the references in the article. ...
- Use search tools and databases to find researchers working on similar topics. ...
- Use your editorial board. ...
- Consider previous authors and guest editors. ...
- Ask reviewers who decline for suggestions. ...
- Use predefined keywords. ...
- Use previous reviewers.
With Google Scholar, you can search by scholar preferences, easily navigate to related articles, and see how many times an article has been cited. Use search criteria to locate peer-reviewed articles.What is the best place to get information about emerging diseases? ›
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) | CDC.How long does it take to review emerging infectious diseases journal? ›
Expect on average 8 weeks from submission to publication.How much does it cost to publish in emerging infectious diseases? ›
Emerging Infectious Diseases is an open access, public domain journal. The journal does not charge fees for submitting or processing articles (or require fees or registration to read its content).What is the difference between peer-reviewed and scholarly articles? ›
In short, “scholarly” means the article was written by an expert for an audience of other experts, researchers or students. “Peer-reviewed” takes it one step further and means the article was reviewed and critiqued by the author's peers who are experts in the same subject area.Are all articles on Google Scholar peer-reviewed? ›
If you find articles in Google Scholar, you would have to look up the journal the article is published in to find out whether they use peer review or not. When using library databases, there are options to restrict to peer review, either from the main search page or usually in the left hand column of the results page.
Is CDC peer-reviewed? ›
We publish peer-reviewed articles of interest to public health researchers and practitioners. If you would like more information on a specific problem or condition, please visit the homepage for the Centers for Disease Control and Prevention (CDC) at www.cdc.gov or call the CDC information number at 1-800-232-4636.